Neurizon Therapeutics Limited · ASX:NUZ
Neurizon Therapeutics — Investor Presentation (April 2026)
17 slides from Neurizon Therapeutics's investor presentation, Apr 10, 2026
Slide 1: Company Presentation April 2026
For personal use only Company Presentation April 2026 ABN 35 094 006 023
Slide 2: Disclaimer
Disclaimer For personal use only This disclaimer applies to this presentation and the information contained in it (This presentation has been Future Matters prepared by Neurizon Therapeutics Limited (ASX: NUZ) (the “Company”)). It does not purport to contain all the information that a prospective in
Slide 3: Our Vision
For personal use only Our Vision To lead the development of neurodegenerative treatments towards a promising new horizon for patients.
Slide 4: Our Promise
Accelerating Patient Driving Hope and Access to Clinical For personal use only Innovative ALS Our Promise Treatment Progress Unlocking the potential Delivering commercial of Neurizon to address readiness and high unmet need in stakeholder neurodegenerative value diseases
Slide 5: Corporate Overview
Corporate Overview Mid-stage biotechnology company targeting human neurodegenerative diseases Share Price Performance Capital Structure (AUD$) 07 April 2026 Current Share Price (NUZ/NUZOA) $0.085/ $0.01 For personal use only Closing Price (AUD$) Volume (m) 0.50 6 52 Week Low / High (NUZ) $0. 078/ $0
Slide 6: NUZ-001: Potential application to range of neurodegenerative diseases
NUZ-001: Potential application to range of neurodegenerative diseases ALS is a current priority, but NUZ-001 has potential application to a range of neurodegenerative diseases. For personal use only NUZ-001 is a mechanism-driven, disease-agnostic approach to treating New preclinical data show NUZ-00
Slide 7: HEALEY Trial: Opportunity for accelerated approval
HEALEY Trial: Opportunity for accellerated approval Initial focus is ALS, a rare disease with high unmet need and the possibility of accelerated approval on Phase 2/3 data. Potential for broader application being developed through pre-clinical program. For personal use only Drug / Approved/ Next Maj
Slide 8: Expanding Relationship with Elanco
Expanding Relationship with Elanco Supply Agreement execution expected in Q2 CY2026 For personal use only License Agreement Strategic Investment Supply Agreement The License Agreement was a foundational step that Elanco is now a top five shareholder in Neurizon and Finalisation of this important agr
Slide 9: Regimen-I HEALEY ALS Platform Trial Expected Key Milestones
‘Regimen-I’ HEALEY ALS Platform Trial Expected Key Milestones For personal use only Q4 2025 Q4 2025 Q1 2026 Q1 2026 Q3-Q4 2026 Q2-Q3 2027 Q3 2027 Q3 2027 5 6 7 8 IND Amendment FDA First Patient First Patient Dosed Enrollment Last Patient Database Topline Data Submission Clearance Screened Complete D
Slide 10: HEALEY ALS Platform Trial Regimen I for NUZ-001
HEALEY ALS Platform Trial Regimen ‘I’ for NUZ-001 36-week Double blind Placebo 36-week Active Treatment Controlled Period Extension Period For personal use only NUZ-001 10 mg/kg Inclusion/Exclusion Criteria 3:1 Randomization NUZ-001 n=160 participants 10 mg/kg QD Placebo Primary Endpoint • Change fr
Slide 11: Regimen I Participant Enrollment Update
Regimen “I” Participant Enrollment Update For personal use only 44 13 Activated Sites Regimen Assignment 46 8 Master Screening Dosed Participants Numbers referred to above are as of 9 April 2026. Company Presentation April 2026 11
Slide 12: HEALEY: Funding secured
HEALEY: Funding secured Strong shareholder support has secured adequate funding for HEALEY ALS Platform trial1 Neurizon’s funding strategy has been developed with a focus on protecting shareholders’ interests through flexible funding instruments and minimising dilution. This includes the ability to
Slide 13: ALS presents compelling commercial opportunity
ALS presents compelling commercial opportunity NUZ-001 targets underlying TDP 43 pathology present in 97% ALS patients. Given the high, unmet need in ALS, it presents a compelling commercial opportunity. For personal use only ALS Patient Population1 ALS Value Reference Point: Shionogi–RADICAVA US$2.
Slide 14: NUZ-001: Strong portfolio protection
NUZ-001: Strong portfolio protection In addition to patent protection, NUZ-001 has US Orphan Drug Designation (ODD) and European Orphan Medicinal Product Designation (OMPD) providing 7 and 10 years of market exclusivity, respectively. For personal use only Patent Families for monepantel 2015 2020 20
Slide 15: Demonstrating Meaningful Progress
Demonstrating Meaningful Progress For personal use only Executed Global Regimen “I” Successful Secured registered Promising Australian License commenced in the manufacture of trademark exploratory top- Patent granted Agreement with HEALEY ALS three registration protection for line results from for N
Slide 16: Near-Term Milestones and Objectives
Near-Term Milestones Objectives For personal use only • Preclinical Updates ✓ HEALEY ALS Platform Trial– IRB Approval th • Commercial Supply Agreement with Elanco ✓44 J.P. Morgan Annual Healthcare Conference and other events • Ethics Approval for Liquid Formulation PK Study ✓Australian R&D Refund (n
Slide 17: NUZ-001: Orphan Drug Designated Small Molecule
NUZ-001: Orphan Drug Designated Small Molecule Showing Promising Survival Trends in ALS For personal use only Well-characterised Drug Current ALS Treatments • First-in-class oral small molecule ✓ ✓ • High unmet need for disease modifying • Validated blood brain barrier penetration treatment • Suppor
Neurizon Therapeutics — Investor Presentation (April 2026) on 6ix